Enfortumab vedotin-ejfv (solution), CAS 1346452-25-2

Product Description: Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Halford Z, et al. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother. 2021 Jun;55(6):772-782./[2]Chang E, et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Feb 15;27(4):922-927.

CAS Number: 1346452-25-2

Molecular Weight: 152000 (average)

Compound Purity: 99.78

Research Area: cancer

Solubility: 10 mM in DMSO

Target: Antibody-Drug Conjugates (ADCs);Nectin-4

• SKU: MEXHY-P99016B-1
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-P99016B-1
• Package Unit: 1 mg
• Quantity Unit: STK